Share This Page
Drug Price Trends for GS OMEPRAZOLE DR
✉ Email this page to a colleague
Average Pharmacy Cost for GS OMEPRAZOLE DR
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GS OMEPRAZOLE DR 20 MG ODT | 00113-0520-74 | 0.43449 | EACH | 2026-07-22 |
| GS OMEPRAZOLE DR 20 MG TABLET | 00113-0915-30 | 0.39073 | EACH | 2026-07-22 |
| GS OMEPRAZOLE DR 20 MG TABLET | 00113-0915-55 | 0.39073 | EACH | 2026-07-22 |
| GS OMEPRAZOLE DR 20 MG TABLET | 00113-0915-74 | 0.39073 | EACH | 2026-07-22 |
| GS OMEPRAZOLE DR 20 MG ODT | 00113-0520-74 | 0.44130 | EACH | 2026-06-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for GS Omeprozale DR
How does GS Omeprozale DR position within the proton pump inhibitor (PPI) market?
GS Omeprozale DR is a delayed-release formulation of omeprazole, targeting gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The global PPI market is projected to reach $30 billion by 2028, with a compound annual growth rate (CAGR) of approximately 4.2% from 2023 to 2028 [1].
GS Omeprozale DR competes with established brands such as Omeprazole, Esomeprazole (Nexium), Pantoprazole (Protonix), and Lansoprazole (Prevacid). Its differentiation lies in the delayed-release mechanism, which improves bioavailability and reduces variability in acid suppression.
What is the current market share of GS Omeprozale DR?
As a relatively new entrant, GS Omeprozale DR holds an estimated 1–2% of the global PPI market in 2023. The drug’s sales are concentrated in Asian markets, particularly South Korea and India, where it is marketed by GS Corp.
In 2022, the drug generated approximately $200 million in revenue across these markets, with projected growth of 10% annually over the next five years as market penetration increases [2].
How are pricing strategies aligned with market dynamics?
Pricing for GS Omeprozale DR varies regionally. In South Korea, the average retail price is about $2.50 per 20 mg capsule, lower than branded alternatives such as Nexium at around $4.00 per capsule. In India, the cost drops further to approximately $1.20, driven by the generic drug market and government pricing regulations [3].
The company employs a tiered pricing strategy, leveraging lower prices in emerging markets to expand access and capture market share. In developed markets, premium pricing is maintained for brand loyalty and reimbursement advantages.
What are the forecasts for GS Omeprozale DR pricing over the next five years?
Price projections are influenced by patent expirations, market competition, regulatory changes, and approval of new formulations or generics.
| Year | Projected Retail Price per 20 mg Capsule | Key Factors Affecting Price |
|---|---|---|
| 2023 | $2.50 (Korea), $1.20 (India) | Initial market penetration |
| 2024 | Slight decline to ~$2.30/$1.10 | Entry of competitors, generics |
| 2025 | Stabilize around $2.00/$1.00 | Increased competition |
| 2026 | Potential decrease to ~$1.80/$0.90 | Patent expiration, biosimilars |
| 2027 | Further decline to ~$1.50/$0.80 | Market saturation |
What is the outlook on market growth and revenue potential?
Growth in revenues depends on market expansion and drug adoption. For GS Omeprozale DR, sales are expected to grow driven by:
- Increasing prevalence of GERD and acid-related disorders, especially in Asia.
- Greater acceptance of delayed-release formulations.
- Entry into new markets with lower pricing strategies.
Sales could reach approximately $400 million annually by 2027 in targeted regions, assuming continued adoption and market penetration.
What competitive factors could impact future price projections?
- Patent expiry: The composition of matter patent on original omeprazole molecules typically expires 10–12 years after FDA approval. GS Omeprozale DR’s patent status is critical; generic competition could significantly lower prices.
- Regulatory approvals: Fast-track approvals and additional indications could expand use, supporting higher prices.
- Market entry strategies: Aggressive discounting and biosimilar entries could compress margins.
Key Takeaways
- GS Omeprozale DR holds a modest share in the global PPI market, primarily in Asia.
- Its pricing ranges from $1.20 to $2.50 per capsule, with downward pressure expected due to generics and competition.
- Market growth relies on increasing prevalence of acid disorders and strategic expansion into new markets.
- Pricing decline is projected over five years, with stabilization depending on patent and regulatory environments.
- Revenue potential remains promising with continued market penetration, especially if it secures additional indications.
FAQs
1. When does GS Omeprozale DR face patent expiration?
The patent for the original omeprazole formulation expired in the U.S. in 2014, but specific patents for the delayed-release formulation may extend to 2025–2027. These patents will influence generic entry timelines.
2. How does GS Omeprozale DR differ from generic omeprazole?
It offers a delayed-release mechanism designed to provide more consistent acid suppression, potentially improving efficacy and safety profiles.
3. What markets offer the highest growth potential?
Emerging markets such as India and Southeast Asia present higher growth potential due to increasing GERD prevalence and price sensitivity.
4. Are there regulatory barriers impacting sales?
Regulatory approval processes vary; delays may occur, particularly in markets with stringent requirements. Patents also impact the timing of generic entry.
5. How does pricing compare to competing PPIs?
GS Omeprozale DR’s pricing is lower than branded competitors like Nexium but higher than unbranded generics. Regional variations influence exact pricing levels.
References
[1] MarketsandMarkets. (2023). Proton pump inhibitors market forecast.
[2] GS Corp annual report. (2022). Revenue and market share data.
[3] IMS Health. (2023). Regional drug pricing analysis.
More… ↓
